Literature DB >> 32052660

Carvedilol Diminishes Cardiac Remodeling Induced by High-Fructose/High-Fat Diet in Mice via Enhancing Cardiac β-Arrestin2 Signaling.

Wael S Ibrahim1,2, Islam A A E-H Ibrahim1, Mona F Mahmoud1, Amr A A Mahmoud1,3.   

Abstract

BACKGROUND: Insulin resistance (IR) is a well-known risk factor for cardiovascular complications. This study aimed to investigate the effect of a dietary model of IR in mice on cardiac remodeling, cardiac β-arrestin2 signaling, and the protective effects of carvedilol as a β-arrestin-biased agonist. METHODS AND
RESULTS: Insulin resistance was induced by feeding mice high-fructose/high-fat diet (HFrHFD) for 16 weeks. Carvedilol was adiministered for 4 weeks starting at week 13. At the end of the experiment, body weight, heart weight, left and right ventricular thickness, visceral fat weight, fasting blood glucose (FBG), serum insulin, IR index, and serum endothelin-1 were measured. In addition, cardiac tissue samples were histopathologically examined. Also, cardiac levels of cardiotrophin-1, β-arrestin2, phosphatidylinositol 4,5 bisphosphate (PIP2), diacylglycerol (DAG), and phosphoserine 473 Akt (pS473 Akt) were measured. Results showed significant increases in the FBG, serum insulin, IR index, serum endothelin-1, cardiac DAG, cardiac fibrosis, and degenerated cardiac myofibrils in HFrHFD-fed mice associated with a significant reduction in cardiac levels of cardiotrophin-1, β-arrestin2, PIP2, and pS473 Akt. On the other hand, carvedilol significantly reduced the heart weight, FBG, serum insulin, IR index, serum endothelin-1, cardiac DAG, left ventricular thickness, right ventricular fibrosis, and degeneration of cardiac myofibrils. In addition, carvedilol significantly increased cardiac levels of cardiotrophin-1, β-arrestin2, PIP2, and pS473 Akt.
CONCLUSION: Carvedilol enhances cardiac β-arrestin2 signaling and reduces cardiac remodeling in HFrHFD-fed mice.

Entities:  

Keywords:  cardiac remodeling; carvedilol; insulin resistance; β-arrestin

Year:  2020        PMID: 32052660     DOI: 10.1177/1074248420905683

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  2 in total

1.  Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4.

Authors:  Rasha M S M Mohamed; Shimaa M Elshazly; Ola E Nafea; Dalia M Abd El Motteleb
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-08-16       Impact factor: 3.000

2.  Carvedilol ameliorates dexamethasone-induced myocardial injury in rats independent of its action on the α1-adrenergic receptor.

Authors:  Rasha M S M Mohamed; Enssaf Ahmad Ahmad; Bothina H F Omran; Amr T Sakr; Islam A A E-H Ibrahim; Mona F Mahmoud; Mostafa E El-Naggar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-09-10       Impact factor: 3.195

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.